SSG
RNAM

Summit Securities Group’s Avidity Biosciences RNAM Stock Holding History

Summit Securities Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,000
Closed -$289K – 1322
2025
Q4 		$289K Buy
+4,000
New +$258K 0.04% 267

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Summit Securities Group's RNAM Position: Q1 2026 in Review

Summit Securities Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 4,000 shares — an estimated $289K sold.

Summit Securities Group first reported a position in RNAM in Q4 2025 and held it in 1 quarter. The position peaked at $289K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Summit Securities Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Summit Securities Group sold 4,000 Avidity Biosciences shares in Q1 2026, an estimated $289K.
  • Summit Securities Group first reported a position in Avidity Biosciences in Q4 2025 and held it in 1 quarter.
  • Summit Securities Group's Avidity Biosciences position peaked at $289K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.